Conference Opening

Welcome

Johnsee Lee, Chairman of BIO Asia–Taiwan 2024
Chung-Hsiun Wu, Chairman, Taiwan Bio Industry Organization
John F. Crowley, President and CEO, Biotechnology Innovation Organization (BIO)

Session Chair

Chung-Hsiun Wu, Chairman, Taiwan Bio Industry Organization

【Industry Policy Lecture】

Impact of Key Policy Changing on Biopharma Industry

John A. Murphy, III, Chief Policy Officer Deputy Counsel, Healthcare, Biotechnology Innovation Organization (BIO)

【Industry Leader Lecture】

Pioneering Entrapeuier Value Creation

【Tang Prize Lecture】

Exploration of Biological Diversity

Feng Zhang, Professor, Massachusetts Institute of Technology

Opening Remarks

Lee-Cheng Liu, Dr. Sci. Eng., Founder, Chairman and President of EirGenix, Inc.

Challenges of Regulatory Considerations

Heidi Wang, Chief Executive Officer, OBI Pharma

Investment Perspectives for ADC Development

Gur Roshwalb, Partner, aMoon

Technology or solutions of Antibody Drug Conjugate (ADC)

Panel Discussion

Moderator:
Lee-Cheng Liu, Dr. Sci. Eng., Founder, Chairman and President of EirGenix, Inc.

Panelists:

• Heidi Wang, Chief Executive Officer, OBI Pharma
• Gur Roshwalb, Partner, aMoon
• Edward Hsieh, Vice President of RD, Formosa Laboratories, Inc.

Opening Remarks

Cell and Gene Therapies Updates

Dr.John Tsai, CEO, Forcefield Therapeutics Executive Partner, Syncona

Driving the Next Generation of Innovative and Affordable Cell Therapies across Indications.

Alex Huang, VP, Head of Cell Therapy, BeiGene

Clinical Trials Design and Execution

Speaker from Amarex

The Perspectives from Investors on Cell and Gene Therapy

Gur Roshwalb, Partner, aMoon

Closing

Opening Remarks

Han-Chung Wu, Director, Biomedical Translation Research Center (BioTReC), Academia Sinica, Taiwan

New Therapeutic Modalities for Treatment of Human Diseases

Yusuke Nakamura, President, National Institutes of Biomedical Innovation, Health and Nutrition

Updates for Gene Therapies-An Industry Perspective

John Tsai, CEO, Forcefield Therapeutics, Executive Partner, Syncona

Initiated from Unthinkable with the Optimization

Eric Huang, Former GM and CSO, Moderna Genomics

CMC Strategy for mRNA-LNP Vaccines and Therapeutics

Kelvin Chan, Director of Commercial & Business Development, Kudo Biotechnology

Closing Remarks

Han-Chung Wu, Director, Biomedical Translation Research Center (BioTReC), Academia Sinica, Taiwan

Opening Remarks

Bobby Sheng, Chairman & CEO, Bora Pharmaceuticals & Bora Biologics

Dr. Art Chu, CEO, T-E Meds

Dr. Paul Song, CSO, GeneQuantum Healthcare

Friedmund Bachmann, VP CMC, OnceOne

Panel Discussion

Moderator:

Panelists:

• Dr. Art Chu, CEO, T-E Meds
• Dr. Paul Song, CSO, GeneQuantum Healthcare
• Friedmund Bachmann, VP CMC, OnceOne

Bobby Sheng, Chairman & CEO, Bora Pharmaceuticals & Bora Biologics

Opening Remarks

Huey-Kang Sytwu, President, National Health Research Institutes

Moderator:
Hsing-Pon Hsieh, Director, Institute of Biotechnology and Pharmaceutical Research (IBPR), National Health Research Institutes

From Bench to Bedside-from Kyprolis in Proteolix to PROTAC in Arvinas (TBD)

GLP-1: From Anti-Diabetic to Anti-Obesity (TBD)

TBD

Panel Discussion

Moderator:
Hsing-Pon Hsieh, Director, Institute of Biotechnology and Pharmaceutical Research (IBPR), National Health Research Institutes
Panelists:
All speakers

Opening Remarks

The Future Now : AI and Drug Discovery

Unlocking the Potential of AI for High-Throughput Immunotherapy, Drug Discovery Through RNA Splicing

Martin Akerman, Co-Founder & CTO, Envisagenics

Integrating Artificial Intelligence in the Design and Discovery of Novel Protein Degraders

Shu-Jen Chen, Ph.D., Chief Scientific Officer, AnHorn Medicines

AI for Pharma: Clinical Perspective

Speaker from Medidata

Closing Remarks

Opening Remarks

Kang-Yun Lee, Vice President, Taipei Medical University

Development of Peptide-Based PPI Inhibitor Targeting the BIG3-PHB2 cancer specific complex for Breast Cancer

Toyomasa Katagiri, Director, National Institutes of Biomedical Innovation, Health and Nutrition

Topic (TBC)

Pankaj J. Pasricha, Mayo Clinic Associate Medical Director - AZ, Business Development

Development of Precision Respiratory Medicine for chronic inflammation and infection

Kazuhiro Ito, Professor, Imperial College London

Panel Discussion

Moderator:

• Teh-Ying Chou, Vice Superintendent for Research and Development, Director, Precision Medicine Research Center, Taipei Medical University Hospital

Panelist:

• Pankaj J. Pasricha, Mayo Clinic ASSOCIATE MEDICAL DIRECTOR - AZ, BUSINESS DEVELOPMENT
• Kazuhiro Ito, Professor, Imperial College London
• Sungmei Hsiung, Partner and Law & Tech Innovation Service Leader, Deloitte Legal

Opening Remarks

Representative from MOEA, Taiwan
Eric Y. Chuang, General Director, Biomedical Technology and Device Research
Laboratories (BDL), ITRI

Digital Health Trends and Global Business Strategies Between Pharma and Start- ups

• Representative from AstraZeneca
• Representative from Google

Panel Discussion: Bridging the Gap – Expand the Cross-Disciplinary Digital Health Community

Moderator:
Eric Y. Chuang, General Director, BDL, ITRI

Panelists:

• Representative from AstraZeneca
• Representative from Google
• Representative from VC
• Kai-Cheng Hsu, Chief Medical Officer (CMO), Biomedical Technology and Device Research Laboratories (BDL), ITRI